BTCY has performed well since our initial report on October 7th, 2021 at $2.95/share. Now trading at $4.41/share. The Growth in revenues and potential FDA clearance of Biotres any day now could catapult this one much farther.
If you missed our full and most recent report I have provided a copy below.
With the New BioHeart Product Just Released Biotricity (BTCY) Could See Revenues and Their Valuation Climb Even Higher
Good day everyone,
Biotricity, Inc. (NASDAQ: BTCY), is a medical diagnostic and consumer healthcare technology company providing biometric data monitoring solutions.
Current price $4.26/share (+.95% at market close 11-10-21)
BTCY reached a high for the day of $4.73/share before following the NASDAQ index into an afternoon slump. Trading volume was moderate at 556K shares.
It can be difficult to determine a value for small-cap companies in the biomedical sector. Many of them are in the nascent stages of development, even BTCY with its ever-increasing revenues. Applying typical valuation methods can makes us come up short, missing a terrific opportunity. Often with biomedical companies we must evaluate where they will be in the near term, mid-term, and long term.
BTCY isn’t the only player in remote cardiac monitoring, the big pharma companies such as Abbot, Boston Scientific, and Medtronic have their own devices on the market. Since I couldn’t find a company similar in scope to BTCY in the cardiac sector, I looked at diabetes, another sector in the initial stages of remote monitoring.
Again, I found companies with valuations in the billions of dollars except for one called DarioHealthcare (DRIO). Dario is a NASDAQ company, just now ramping up sales ($12M ttm). Dario is also an exciting small company with new MedTech products, similar to BTCY in scope except their market cap is $306M. Ironically, if BTCY shares were at $7.00, the consensus analyst target I mentioned before, the BTCY company valuation would be $333M.
But BTCY is the one perfecting the wireless link between the remote cardiac monitoring device and the physician. I think that feature will set BTCY apart from remote monitoring systems developed by competitors.
I want to talk briefly about Dr. Waqaas Al-Siddiq, DBA, the founder and CEO of Biotricity. I have said before that top management can be a determining factor in the success and growth of any company and BTCY has a top-notch leader. I’ve watched videos of him, read his statements in press releases, and checked out his LinkedIn page where there’s a list of sixty interviews he’s given over the last five years.
Waqaas is smart, energetic, confident, and a visionary company leader. He knows exactly where he wants to take Biotricity, how they are going to get there, and he knows BTCY from the inside out. Waqaas also understands the need for stakeholder value.
He is a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council.
Waqaas has held several high-level design positions in IBM, AMD, and Intel. His achievements have been numerous in both the technical and academic world. Coupled with this, Waqaas has vast experience in leading various groups through his board experience and executive roles within start-ups, mid-sized companies, and non-profits.
Waqaas has a dual bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration from Henley Business School. He also holds a Doctorate in Business with a specialty in Transformative Innovations and Billion Dollar Markets.
Institutions investing in BTCY:
Old Second National Bank of Aurora 15,000 Jun 29, 2021
Signature Wealth Management Partners, LLC 12,000 Sep 29, 2021
StoneX Group Inc. 10,959 Sep 29, 2021
Cedar Mountain Advisors, LLC 5,000 Sep 29, 2021
Advisor Group, Inc. 3,700 Sep 29, 2021
For a full description of the company’s operations and financial standing, I recommend as a part of your due diligence that you review the BTCY form 10-Q filed on November 4, 2021. I will be watching BTCY and reporting on future catalysts as they come.
The Traders News Group
Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
https://tradersnewssource.com/cookie-policy-us/
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.